ES2341252T3 - Composiciones que comprenden polipeptidos. - Google Patents
Composiciones que comprenden polipeptidos. Download PDFInfo
- Publication number
- ES2341252T3 ES2341252T3 ES04803302T ES04803302T ES2341252T3 ES 2341252 T3 ES2341252 T3 ES 2341252T3 ES 04803302 T ES04803302 T ES 04803302T ES 04803302 T ES04803302 T ES 04803302T ES 2341252 T3 ES2341252 T3 ES 2341252T3
- Authority
- ES
- Spain
- Prior art keywords
- polypeptide
- antigen
- multimeric
- monomeric
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 308
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 297
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 297
- 239000000203 mixture Substances 0.000 title claims abstract description 101
- 239000000427 antigen Substances 0.000 claims abstract description 205
- 102000036639 antigens Human genes 0.000 claims abstract description 205
- 108091007433 antigens Proteins 0.000 claims abstract description 205
- 239000000463 material Substances 0.000 claims description 52
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 43
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 27
- 239000000872 buffer Substances 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 19
- 238000000926 separation method Methods 0.000 claims description 15
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 239000000178 monomer Substances 0.000 claims description 12
- 238000004587 chromatography analysis Methods 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 238000010828 elution Methods 0.000 claims description 10
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 9
- 239000008363 phosphate buffer Substances 0.000 claims description 9
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 8
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 8
- 230000006872 improvement Effects 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000012545 processing Methods 0.000 claims description 7
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 239000002243 precursor Substances 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 4
- 238000005349 anion exchange Methods 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 229910021645 metal ion Inorganic materials 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 208000007660 Residual Neoplasm Diseases 0.000 claims description 3
- 208000030961 allergic reaction Diseases 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 230000007717 exclusion Effects 0.000 claims description 3
- 238000002270 exclusion chromatography Methods 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 3
- 230000003071 parasitic effect Effects 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 230000005945 translocation Effects 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 238000009413 insulation Methods 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 238000004440 column chromatography Methods 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000009897 systematic effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 61
- 210000001744 T-lymphocyte Anatomy 0.000 description 34
- 241000894007 species Species 0.000 description 27
- 230000004071 biological effect Effects 0.000 description 26
- 238000010276 construction Methods 0.000 description 17
- 239000012636 effector Substances 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 16
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 11
- 230000004913 activation Effects 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 230000009089 cytolysis Effects 0.000 description 8
- 239000000539 dimer Substances 0.000 description 8
- 230000001472 cytotoxic effect Effects 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 6
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 4
- 231100000050 cytotoxic potential Toxicity 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011285 therapeutic regimen Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 3
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 3
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- YDVYLSIVXYLBBX-UHFFFAOYSA-N 1,2,3-trichloro-4-(2,3,6-trichlorophenoxy)benzene Chemical compound ClC1=C(Cl)C(Cl)=CC=C1OC1=C(Cl)C=CC(Cl)=C1Cl YDVYLSIVXYLBBX-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 0 CC(C(*)C(C(C(C*)O)N)O)O Chemical compound CC(C(*)C(C(C(C*)O)N)O)O 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 101710147220 Ent-copalyl diphosphate synthase, chloroplastic Proteins 0.000 description 1
- 239000012541 Fractogel® Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- 101800000385 Transmembrane protein Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- -1 for example Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03027511 | 2003-11-28 | ||
| EP03027511 | 2003-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2341252T3 true ES2341252T3 (es) | 2010-06-17 |
Family
ID=34626385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES04803302T Expired - Lifetime ES2341252T3 (es) | 2003-11-28 | 2004-11-26 | Composiciones que comprenden polipeptidos. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10000574B2 (OSRAM) |
| EP (2) | EP2186527A1 (OSRAM) |
| AT (1) | ATE459374T1 (OSRAM) |
| AU (1) | AU2004293182B2 (OSRAM) |
| BE (1) | BE2016C023I2 (OSRAM) |
| CA (1) | CA2544532C (OSRAM) |
| CY (2) | CY1110689T1 (OSRAM) |
| DE (1) | DE602004025840D1 (OSRAM) |
| DK (1) | DK1691833T3 (OSRAM) |
| ES (1) | ES2341252T3 (OSRAM) |
| FR (1) | FR16C1000I2 (OSRAM) |
| HU (1) | HUS1600019I1 (OSRAM) |
| LU (1) | LU93067I2 (OSRAM) |
| NL (1) | NL300807I2 (OSRAM) |
| PL (1) | PL1691833T3 (OSRAM) |
| PT (1) | PT1691833E (OSRAM) |
| SI (1) | SI1691833T1 (OSRAM) |
| WO (1) | WO2005052004A2 (OSRAM) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME01786B (me) | 2006-08-14 | 2014-09-20 | Xencor Inc | Optimizovana antitela usmerena na cd19 |
| PL2066349T3 (pl) | 2006-09-08 | 2012-09-28 | Medimmune Llc | Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych |
| WO2009070642A1 (en) * | 2007-11-28 | 2009-06-04 | Medimmune, Llc | Protein formulation |
| US8658765B2 (en) | 2009-12-31 | 2014-02-25 | Avidbiotics Corp. | Non-natural MIC proteins |
| US8796420B2 (en) | 2009-12-31 | 2014-08-05 | Avidbiotics Corp. | Non-natural MIC proteins |
| SMT202000232T1 (it) | 2010-10-27 | 2020-07-08 | Amgen Res Munich Gmbh | Metodi per trattare dlbcl |
| EP2686020B1 (en) | 2011-03-17 | 2017-02-22 | The University of Birmingham | Re-directed immunotherapy |
| CA2833019A1 (en) | 2011-04-22 | 2012-10-26 | Emergent Product Development Seattle, Llc | Prostate-specific membrane antigen binding proteins and related compositions and methods |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| HUE047699T2 (hu) | 2013-12-17 | 2020-05-28 | Hoffmann La Roche | Eljárások rákbetegségek kezelésére PD-1-tengelyhez kötõdõ antagonisták és taxánok alkalmazásával |
| CN105899535A (zh) | 2013-12-17 | 2016-08-24 | 豪夫迈·罗氏有限公司 | 用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法 |
| MA40069A (fr) | 2014-05-29 | 2021-04-14 | Macrogenics Inc | Molécules de liaison trispécifiques et leurs procédés d'utilisation |
| CN107075548B (zh) | 2014-11-05 | 2021-08-10 | 基因泰克公司 | 在细菌中产生双链蛋白质的方法 |
| CN108064308B (zh) | 2014-11-05 | 2023-06-09 | 豪夫迈·罗氏有限公司 | 细菌中产生双链蛋白的方法 |
| CN107427590B (zh) | 2015-02-02 | 2021-08-31 | 伯明翰大学 | 具有多个t细胞表位的靶向部分肽表位复合物 |
| EP3303619B1 (en) | 2015-05-29 | 2020-06-10 | H. Hoffnabb-La Roche Ag | Pd-l1 promoter methylation in cancer |
| WO2016205320A1 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
| MY197562A (en) | 2015-09-21 | 2023-06-23 | Aptevo Res & Development Llc | Cd3 binding polypeptides |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| WO2017087789A1 (en) | 2015-11-19 | 2017-05-26 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| WO2017097723A2 (en) | 2015-12-09 | 2017-06-15 | F. Hoffmann-La Roche Ag | Treatment method |
| EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
| IL259588B2 (en) | 2016-01-08 | 2023-09-01 | Hoffmann La Roche | Methods for the treatment of cea-positive cancer using pd-1 spindle-binding antagonists and bispecific antibodies against anti-cea and anti-cd3 |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| US11046776B2 (en) | 2016-08-05 | 2021-06-29 | Genentech, Inc. | Multivalent and multiepitopic antibodies having agonistic activity and methods of use |
| WO2018029124A1 (en) | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
| EP3554542A1 (en) | 2016-12-19 | 2019-10-23 | H. Hoffnabb-La Roche Ag | Combination therapy with targeted 4-1bb (cd137) agonists |
| EP3559034B1 (en) | 2016-12-20 | 2020-12-02 | H. Hoffnabb-La Roche Ag | Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists |
| EP3630829A1 (en) | 2017-06-02 | 2020-04-08 | H. Hoffnabb-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| KR20200084006A (ko) | 2017-11-01 | 2020-07-09 | 에프. 호프만-라 로슈 아게 | 표적화된 ox40 작용제를 사용하는 병용 요법 |
| TWI841551B (zh) | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | 使用靶向4-1bb (cd137)之促效劑的組合療法 |
| KR102836393B1 (ko) | 2018-03-13 | 2025-07-22 | 에프. 호프만-라 로슈 아게 | 4-1bb 작용제와 항-cd20 항체의 치료 조합 |
| CN113195544A (zh) * | 2018-06-07 | 2021-07-30 | 库利南肿瘤股份有限公司 | 多特异性结合蛋白及其使用方法 |
| AU2019342133B8 (en) | 2018-09-21 | 2025-08-07 | Genentech, Inc. | Diagnostic methods for triple-negative breast cancer |
| SG11202104104VA (en) | 2018-11-05 | 2021-05-28 | Genentech Inc | Methods of producing two chain proteins in prokaryotic host cells |
| WO2020221792A1 (en) | 2019-04-30 | 2020-11-05 | Amgen Research (Munich) Gmbh | Means and methods of treating burkitt lymphoma or leukemia |
| IL288024B1 (en) | 2019-05-14 | 2025-08-01 | Provention Bio Inc | Methods and compositions for preventing type |
| WO2020236792A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Cd19 binding molecules and uses thereof |
| CA3161283A1 (en) | 2019-12-11 | 2021-06-17 | Cullinan Oncology, Inc. | Anti-cd19 antibodies and multi-specific binding proteins |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| KR20230025691A (ko) | 2020-06-16 | 2023-02-22 | 제넨테크, 인크. | 삼중 음성 유방암을 치료하기 위한 방법과 조성물 |
| KR102453073B1 (ko) * | 2020-08-14 | 2022-10-11 | 건국대학교 글로컬산학협력단 | 피키아 파스토리스를 이용한 이중특이적 항체의 제조방법 및 이에 따른 이중특이적 항체 |
| EP4288455A1 (en) | 2021-02-03 | 2023-12-13 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| US20240209080A1 (en) | 2021-04-10 | 2024-06-27 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
| US20250066490A1 (en) | 2021-04-23 | 2025-02-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
| EP4083061A1 (en) * | 2021-04-30 | 2022-11-02 | Kilometro Rosso SPA | Fusion proteins and use thereof in the treatment of membranous nephropathy |
| EP4329800A1 (en) | 2021-04-30 | 2024-03-06 | F. Hoffmann-La Roche AG | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
| CN117321078A (zh) | 2021-04-30 | 2023-12-29 | 豪夫迈·罗氏有限公司 | 针对用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物进行组合治疗的给药 |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| IL314211A (en) | 2022-03-23 | 2024-09-01 | Genentech Inc | Combined treatment of bispecific antibody and chemotherapy against CD20/ANTI-CD3 |
| TW202404637A (zh) | 2022-04-13 | 2024-02-01 | 瑞士商赫孚孟拉羅股份公司 | 抗ｃｄ２０／抗ｃｄ３雙特異性抗體之醫藥組成物及使用方法 |
| WO2024030956A2 (en) | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
| WO2024094741A1 (en) | 2022-11-03 | 2024-05-10 | F. Hoffmann-La Roche Ag | Combination therapy with anti-cd19/anti-cd28 bispecific antibody |
| AU2024275646A1 (en) | 2023-05-24 | 2025-11-13 | Mozart Therapeutics, Inc. | Cd8-specific binding proteins and methods of using the same |
| WO2024261013A1 (en) | 2023-06-21 | 2024-12-26 | F. Hoffmann-La Roche Ag | Combination therapy with fap-targeted lymphotoxin beta receptor agonists |
| WO2025072406A1 (en) | 2023-09-26 | 2025-04-03 | Profoundbio Us Co. | Ptk7 binding agents, conjugates thereof and methods of using the same |
| TW202535949A (zh) | 2023-12-20 | 2025-09-16 | 美商必治妥美雅史谷比公司 | 靶向IL-18受體β(IL-18RB)之抗體及相關方法 |
| WO2025149661A1 (en) | 2024-01-10 | 2025-07-17 | Genmab A/S | Slitrk6 binding agents, conjugates thereof and methods of using the same |
| WO2025181219A1 (en) | 2024-02-29 | 2025-09-04 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
| WO2025222129A2 (en) | 2024-04-19 | 2025-10-23 | Mozart Therapeutics, Inc. | Engineered cytokines and targeted cytokine delivery |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| CA2100671C (en) | 1991-02-27 | 1999-02-02 | James S. Huston | Serine rich peptide linkers |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US5656730A (en) * | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| CZ302070B6 (cs) * | 1998-04-21 | 2010-09-29 | Micromet Ag | Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto |
| US20020142964A1 (en) * | 2000-11-02 | 2002-10-03 | Nissen Torben Lauesgaard | Single-chain polypeptides |
| ES2392073T3 (es) * | 2001-11-08 | 2012-12-04 | Abbott Biotherapeutics Corp. | Formulación farmacéutica líquida estable de anticuerpos IGG |
-
2004
- 2004-11-26 AT AT04803302T patent/ATE459374T1/de active
- 2004-11-26 US US10/580,660 patent/US10000574B2/en active Active
- 2004-11-26 ES ES04803302T patent/ES2341252T3/es not_active Expired - Lifetime
- 2004-11-26 WO PCT/EP2004/013445 patent/WO2005052004A2/en not_active Ceased
- 2004-11-26 DK DK04803302.1T patent/DK1691833T3/da active
- 2004-11-26 EP EP10155222A patent/EP2186527A1/en not_active Withdrawn
- 2004-11-26 AU AU2004293182A patent/AU2004293182B2/en not_active Expired
- 2004-11-26 CA CA2544532A patent/CA2544532C/en not_active Expired - Lifetime
- 2004-11-26 PT PT04803302T patent/PT1691833E/pt unknown
- 2004-11-26 EP EP04803302A patent/EP1691833B1/en not_active Expired - Lifetime
- 2004-11-26 SI SI200431360T patent/SI1691833T1/sl unknown
- 2004-11-26 PL PL04803302T patent/PL1691833T3/pl unknown
- 2004-11-26 DE DE602004025840T patent/DE602004025840D1/de not_active Expired - Lifetime
-
2010
- 2010-05-27 CY CY20101100465T patent/CY1110689T1/el unknown
-
2016
- 2016-05-03 NL NL300807C patent/NL300807I2/nl unknown
- 2016-05-05 HU HUS1600019C patent/HUS1600019I1/hu unknown
- 2016-05-05 CY CY2016010C patent/CY2016010I2/el unknown
- 2016-05-10 BE BE2016C023C patent/BE2016C023I2/fr unknown
- 2016-05-11 LU LU93067C patent/LU93067I2/fr unknown
- 2016-05-20 FR FR16C1000C patent/FR16C1000I2/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PT1691833E (pt) | 2010-06-08 |
| SI1691833T1 (sl) | 2010-06-30 |
| AU2004293182A1 (en) | 2005-06-09 |
| FR16C1000I1 (OSRAM) | 2016-06-24 |
| DK1691833T3 (da) | 2010-05-03 |
| BE2016C023I2 (OSRAM) | 2023-12-18 |
| US20070249529A1 (en) | 2007-10-25 |
| LU93067I2 (fr) | 2016-07-11 |
| FR16C1000I2 (fr) | 2017-02-03 |
| CY2016010I1 (el) | 2016-08-31 |
| HUS1600019I1 (hu) | 2016-06-28 |
| NL300807I2 (OSRAM) | 2016-10-13 |
| EP2186527A1 (en) | 2010-05-19 |
| WO2005052004A3 (en) | 2006-03-09 |
| CA2544532A1 (en) | 2005-06-09 |
| CA2544532C (en) | 2015-06-16 |
| CY1110689T1 (el) | 2015-06-10 |
| ATE459374T1 (de) | 2010-03-15 |
| AU2004293182B2 (en) | 2010-02-18 |
| WO2005052004A2 (en) | 2005-06-09 |
| DE602004025840D1 (de) | 2010-04-15 |
| CY2016010I2 (el) | 2016-08-31 |
| EP1691833A2 (en) | 2006-08-23 |
| US10000574B2 (en) | 2018-06-19 |
| PL1691833T3 (pl) | 2010-08-31 |
| EP1691833B1 (en) | 2010-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2341252T3 (es) | Composiciones que comprenden polipeptidos. | |
| ES2773306T3 (es) | Polipéptidos bi o multiespecíficos de unión a antígenos de superficie de células efectoras inmunitarias y antígenos de VHB para tratar infecciones por VHB y estados asociados | |
| CN104379601B (zh) | 双特异性抗体分子和抗原-转染的t-细胞以及它们在医药中的用途 | |
| RU2558301C2 (ru) | Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие | |
| AU2020273695B2 (en) | Antibody against claudin 18A2 and use thereof | |
| EP3858856A1 (en) | Anti-b7-h3 monoclonal antibody and use thereof in cell therapy | |
| CN113272318A (zh) | 用于实体癌的嵌合抗原受体和表达嵌合抗原受体的t细胞 | |
| KR102157701B1 (ko) | 항-코티닌 항체가 연결된 키메라 항체 수용체 및 이의 용도 | |
| KR102613109B1 (ko) | Icam-1 특이적 i 도메인 키메라 항원 수용체 | |
| ES2717308T3 (es) | Células madre pluri- o multi-potentes genéticamente modificadas y sus usos | |
| WO2022057871A1 (zh) | 抗4-1bb-抗pd-l1双特异性抗体、其药物组合物及用途 | |
| CA3025894A1 (en) | Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein | |
| JP2024514246A (ja) | Ｃｌｄｎ１８．２抗原結合タンパク質およびその使用 | |
| WO2022022709A1 (zh) | 一种SIRPα-Fc融合蛋白 | |
| US20210253700A1 (en) | Bispecific binding molecules | |
| CN108840932A (zh) | 一种pd-1特异性抗体及其抗肿瘤应用 | |
| JP2023547661A (ja) | Ｃｄ３に結合するポリペプチド構築物 | |
| CN117777305A (zh) | 多特异性融合蛋白的制备及其应用 | |
| CN110872356B (zh) | 双特异性抗体及其使用方法 | |
| Carosella et al. | Anti-Human interleukin 2 receptor monoclonal antibody isotypic switching: chimeric rat-human antibodies | |
| RU2811431C2 (ru) | Антитело против клаудина 18a2 и его применение | |
| AU2023314375A1 (en) | Combination therapies for treatment of cancer | |
| WO2025201438A1 (zh) | 一种双融合蛋白及其用途 | |
| AU2024257454A1 (en) | Anti-pd-l1 nanobody, preparation method therefor and use thereof | |
| CN119215188A (zh) | 抗Trop2抗体和抗5T4抗体-自然杀伤细胞偶联物及其用途 |